Immutep Limited (IMMP)

NASDAQ: IMMP · IEX Real-Time Price · USD
1.90
+0.04 (2.15%)
At close: Sep 29, 2023, 4:00 PM
1.86
-0.04 (-2.11%)
After-hours: Sep 29, 2023, 4:08 PM EDT
2.15%
Market Cap 169.70M
Revenue (ttm) 4.36M
Net Income (ttm) -24.54M
Shares Out 89.31M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 84,261
Open 1.86
Previous Close 1.86
Day's Range 1.81 - 1.91
52-Week Range 1.50 - 3.90
Beta 1.99
Analysts Strong Buy
Price Target 8.50 (+347.37%)
Earnings Date Oct 30, 2023

About IMMP

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 t... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Marc Voigt
Country Australia
Stock Exchange NASDAQ
Ticker Symbol IMMP
Full Company Profile

Financial Performance

In 2022, Immutep's revenue was 6.76 million, an increase of 70.31% compared to the previous year's 3.97 million. Losses were -32.21 million, 7.72% more than in 2021.

Financial numbers in AUD Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for IMMP stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 347.37% from the latest price.

Price Target
$8.5
(347.37% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achieved Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achieved

10 days ago - GlobeNewsWire

Immutep to Participate in September Investor Conferences

SYDNEY, AUSTRALIA, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapi...

26 days ago - GlobeNewsWire

Immutep Receives Positive Scientific Advice from European Medicines Agency

Media Release SYDNEY, AUSTRALIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...

2 months ago - GlobeNewsWire

Immutep Quarterly Activities Report Q4 FY23

Media Release Late-stage & registrational trial progress: TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational trial in 1st line non-small cell lung cancer (1L NSCLC...

2 months ago - GlobeNewsWire

Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023

Media Release Mini O ral presentation will include data from TACTI-002 Phase II trial evaluating chemotherapy-free IO combination of efti plus KEYTRUDA® ( pembrolizumab) Two additional posters on inv...

2 months ago - GlobeNewsWire

First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Media Release SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...

2 months ago - GlobeNewsWire

Immutep Completes A$80 Million Capital Raise

Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...

3 months ago - GlobeNewsWire

Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor

Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer an...

3 months ago - GlobeNewsWire

Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3

Media Release SYDNEY, AUSTRALIA, June 20, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer an...

3 months ago - GlobeNewsWire

Immutep to Participate at the Jefferies Healthcare Conference

SYDNEY, AUSTRALIA, June 07, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapie...

4 months ago - GlobeNewsWire

Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting

Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response not reached despite median follow up of 39 months in TACTI-...

4 months ago - GlobeNewsWire

Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer

Sydney, Australia, June 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) (Immutep or the Company), is pleased to announce the successful completion of an i...

4 months ago - GlobeNewsWire

Immutep Selects Charles River Laboratories for IMP761's GLP Toxicology Study

Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep's preclinical toxicology study evaluating the safety and toxicity of IMP761 Forms a key step prior to first-in-...

4 months ago - GlobeNewsWire

Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting

Media Release New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma Deep, durable resp...

4 months ago - GlobeNewsWire

Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Media Release SYDNEY, AUSTRALIA, May 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 i...

4 months ago - GlobeNewsWire

Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial

Media Release Efti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung cancer is well tolerated and continues to show promising initial signals of efficacy...

4 months ago - GlobeNewsWire

Immutep's Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Media Release Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II TACTI...

4 months ago - GlobeNewsWire

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Media Release SYDNEY, AUSTRALIA, May 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 i...

4 months ago - GlobeNewsWire

Immutep to Participate in the JMP Securities Life Sciences Conference

Media Release SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 i...

5 months ago - GlobeNewsWire

Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma

Media Release Webinar to take place on Tuesday, May 9, 2023, at 11:30 AM ET SYDNEY, AUSTRALIA, May 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology...

5 months ago - GlobeNewsWire

Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

Media Release Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual immuno-oncology (IO) combination of eftilagimod alpha and BAVENCIO® in metastatic urot...

5 months ago - GlobeNewsWire

Immutep Quarterly Activities Report

Media Release Initiation of integrated Phase II/III AIPAC-003 trial evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cancer and triple-negative breast cancer Positi...

5 months ago - GlobeNewsWire

Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting

Media Release Final results from Part C of the Phase II TACTI-002 trial in 2nd line head and neck squamous cell carcinoma patients to be presented SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) --...

5 months ago - GlobeNewsWire

Immutep Appoints Dr. Florian Vogl as Chief Medical Officer

Media Release SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer ...

5 months ago - GlobeNewsWire

Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting

Media Release Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosis First time efti will be studied in neoadjuvant, non-metastatic cancer setting Novel tri...

5 months ago - GlobeNewsWire